SCIENTIFIC BACKGROUND

ALG1, ALG11, ALG12, ALG13, ALG2, ALG3, ALG6, ALG8, ALG9, B4GALT1, CAD, CCDC115, COG1, COG4, COG5, COG6, COG7, COG8, DDOST, DOLK, DPAGT1, DPM1, DPM2, DPM3, MGAT2, MOGS, MPDU1, MPI, NGLY1, PGM1, PMM2, RFT1, SLC35A1, SLC35A2, SLC35C1, SLC39A8, SRD5A3, SSR4, STT3A, STT3B, TMEM165, TMEM199, TUSC3

Scientific Background

Congenital disorders of glycosylation (CDG syndrome) are hereditary defects of glycoprotein biosynthesis and are genetic metabolic defects. They are usually severe multi-organ diseases with often pronounced neurological disorders. Various subtypes of CDG syndrome are known, which have been grouped according to the location of the respective defect within the cell and not according to clinical aspects. NGS panel diagnostics can currently examine 43 genes for different CDG types.

 

The most common is CDG syndrome type Ia, which is caused by a phosphomannomutase deficiency due to mutations in the PMM2 gene. A pronounced developmental disorder is typical; brain malformations, skeletal anomalies, inverted nipples, coagulation defects and other symptoms may also occur. The suspected diagnosis is usually assessed first using metabolic diagnosis to detect abnormal glycosylation of serum glycoproteins by serum transferrin electrophoresis, and then confirmed by molecular genetic examination. However, evidence of abnormal glycosylation of serum glycoproteins is not present in all types of CDG syndrome. Therefore, if the serum transferrin electrophoresis is inconspicuous and the suspected diagnosis remains, NGS panel diagnostics may be indicated and may lead to a diagnosis in individual cases and thus to more precise statements on the prognosis and the risk of recurrence.

 

References

Gilfix B.M. 2019, Hum Mutat. 40:1010 / Francisco et al. 2019, J Inherit Metab Dis. 42:29 / Francisco et al. 2019, Mol Genet Metab. 126:1 / van Tol et al. 2019, Curr Opin Struct Biol. 56:107 / Chang et al. 2018, Ann Transl Med. 6:477

GENES

ALG1, ALG11, ALG12, ALG13, ALG2, ALG3, ALG6, ALG8, ALG9, B4GALT1, CAD, CCDC115, COG1, COG4, COG5, COG6, COG7, COG8, DDOST, DOLK, DPAGT1, DPM1, DPM2, DPM3, MGAT2, MOGS, MPDU1, MPI, NGLY1, PGM1, PMM2, RFT1, SLC35A1, SLC35A2, SLC35C1, SLC39A8, SRD5A3, SSR4, STT3A, STT3B, TMEM165, TMEM199, TUSC3
How to order

LATEST ARTICLES

Neurodevelopmental disorders (NDDs) have diverse genetic origins, making diagnosis challenging. A new study analyzing over 1,100 pediatric patients f...

Read more

Colorectal cancer (CRC) remains one of the most prevalent and deadly cancers worldwide, with a significant number of cases presenting at an advanced ...

Read more

Carrier screening is a genetic test designed to identify whether an individual carries a gene with changes (mutations) associated with inherited diso...

Read more

Trisomy 13, also known as Patau syndrome, is a genetic condition in which cells in the body have three copies of chromosome 13 instead of two. The co...

Read more

The human brain develops through a complex series of events, with genes carefully regulating the formation of neurons and glial cells. A recent study...

Read more

Rare diseases affect between 300 and 400 million people worldwide – more than cancer and AIDS combined [1, 2], but despite this, many people face a...

Read more

Rosalind Elsie Franklin was a brilliant and meticulous research scientist whose interdisciplinary work made fundamental contributions to various area...

Read more

February, designated as Cancer Awareness Month, marks a time to reflect on the remarkable progress made in cancer research and to inspire hope for th...

Read more

Introduction Cardiovascular disease (CVD) is a major health issue as it remains a leading cause of death worldwide [1]. CVD is responsible for mor...

Read more

Antimicrobial resistance (AMR) is one of the most pressing global health threats, and accurate identification and surveillance of multidrug-resistant...

Read more